153 related articles for article (PubMed ID: 24132401)
1. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.
Ero MP; Harvey NR; Harbert JL; Janc JW; Chin KH; Barriere SL
J Thromb Thrombolysis; 2014; 38(2):235-40. PubMed ID: 24132401
[TBL] [Abstract][Full Text] [Related]
2. Effects of telavancin on coagulation test results.
Barriere SL; Goldberg MR; Janc JW; Higgins DL; Macy PA; Adcock DM
Int J Clin Pract; 2011 Jul; 65(7):784-9. PubMed ID: 21564449
[TBL] [Abstract][Full Text] [Related]
3. Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample.
Searles B; Nasrallah F; Graham S; Lajara RB
J Extra Corpor Technol; 2002 Sep; 34(3):178-81. PubMed ID: 12395962
[TBL] [Abstract][Full Text] [Related]
4. Effect of telavancin (Vibativ) on routine coagulation test results.
Gosselin R; Dager W; Roberts A; Freeman L; Gandy L; Gregg J; Dwyre D
Am J Clin Pathol; 2011 Dec; 136(6):848-54. PubMed ID: 22095369
[TBL] [Abstract][Full Text] [Related]
5. Case report: artificial elevation of prothrombin time by telavancin.
Amanatullah DF; Lopez MJ; Gosselin RC; Gupta MC
Clin Orthop Relat Res; 2013 Jan; 471(1):332-5. PubMed ID: 23129464
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
7. Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
Wieloch M; Hillarp A; Strandberg K; Nilsson C; Svensson PJ
Thromb Res; 2009 Jul; 124(3):344-8. PubMed ID: 19423152
[TBL] [Abstract][Full Text] [Related]
8. Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors.
Niederdöckl J; Dempfle CE; Schönherr HR; Bartsch A; Miles G; Laggner A; Pathil A
Int J Lab Hematol; 2016 Aug; 38(4):426-34. PubMed ID: 27384253
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Study of Point-of-Care Prothrombin Time in Cardiopulmonary Bypass Surgery.
Okabayashi S; Ogawa S; Tanaka KA; Nishiyama T; Takeshita S; Nakayama Y; Nakajima Y; Sawa T; Mizobe T
J Cardiothorac Vasc Anesth; 2018 Aug; 32(4):1609-1614. PubMed ID: 29395816
[TBL] [Abstract][Full Text] [Related]
10. Point-of-care testing of neonatal coagulation.
Tan K; Booth D; Newell SJ; Dear PR; Hughes C; Richards M
Clin Lab Haematol; 2006 Apr; 28(2):117-21. PubMed ID: 16630216
[TBL] [Abstract][Full Text] [Related]
11. Validation of the minimal citrate tube fill volume for routine coagulation tests on ACL TOP 500 CTS®.
Ver Elst K; Vermeiren S; Schouwers S; Callebaut V; Thomson W; Weekx S
Int J Lab Hematol; 2013 Dec; 35(6):614-9. PubMed ID: 23663653
[TBL] [Abstract][Full Text] [Related]
12. Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy.
Jonsson M; Hillarp A; Svensson P
Thromb Res; 2004; 114(2):83-9. PubMed ID: 15306149
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of point of care coagulometers compared to reference laboratory measurements in patients on oral anticoagulation therapy.
Dillinger JG; Si Moussi T; Berge N; Bal Dit Sollier C; Henry P; Drouet L
Thromb Res; 2016 Apr; 140():66-72. PubMed ID: 26901852
[TBL] [Abstract][Full Text] [Related]
14. Results of the performance verification of the CoaguChek XS system.
Plesch W; Wolf T; Breitenbeck N; Dikkeschei LD; Cervero A; Perez PL; van den Besselaar AM
Thromb Res; 2008; 123(2):381-9. PubMed ID: 18585761
[TBL] [Abstract][Full Text] [Related]
15. Comparability of the results of PT-INR with local MNPT and APTTR with MNAPTT on different coagulation analyzers in China.
Peng L; Yan C; Wu X; Nie L
Int J Lab Hematol; 2009 Jun; 31(3):352-8. PubMed ID: 18510575
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prothrombin time derived from CoaguChek XS and laboratory test according to fibrinogen level.
Kim SJ; Lee EY; Park R; Kim J; Song J
J Clin Lab Anal; 2015 Jan; 29(1):28-31. PubMed ID: 24687901
[TBL] [Abstract][Full Text] [Related]
17. Potential dosing errors using portable prothrombin time monitoring devices.
Loebstein R; Kurnik D; Lubetsky A; Ezra D; Halkin H
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):479-83. PubMed ID: 12851534
[TBL] [Abstract][Full Text] [Related]
18. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study.
Toulon P; Ozier Y; Ankri A; Fléron MH; Leroux G; Samama CM
Thromb Haemost; 2009 Feb; 101(2):394-401. PubMed ID: 19190827
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
20. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
